PRIVILEGED AND CONFIDENTIAL — ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP 600 Lexington Avenue, 30th Floor New York, NY 10022
MEMORANDUM
TO: Patrick Gallagher, Lead Associate, Litigation (General) Linda Osei, Responsible Partner, Litigation (General)
FROM: Simone Laroche, Working Associate, Litigation (General)
DATE: September 16, 2025
RE: Preliminary Damages Assessment — Meridian Consumer Brands LLC v. Apex Naturals Inc.
MATTER NO.: 1011-00004
PRIVILEGE DESIGNATION: This memorandum constitutes attorney work product prepared in anticipation of litigation and is protected by the attorney-client privilege and the work-product doctrine. It contains mental impressions, conclusions, opinions, and legal theories of counsel. This memorandum is not intended for distribution outside of Calderwood & Harkness LLP without the prior written authorization of Linda Osei.
I. EXECUTIVE SUMMARY
The purpose of this memorandum is to provide a preliminary quantification of the damages available to Meridian Consumer Brands LLC ("Meridian" or "MCB") in its anticipated federal action against Apex Naturals Inc. ("Apex") arising from Apex's false and misleading comparative advertising campaign marketed under the name "The PuraClear Truth," which was launched nationally on June 2, 2025. This assessment is intended to inform the litigation strategy, support the forthcoming motion for preliminary injunctive relief, and provide a framework for the formal damages model that Dr. Raymond Choe of Marlowe Asset Management Economic Consulting LLC will prepare upon engagement.
This memorandum analyzes three principal categories of recoverable damages:
1. Compensatory Damages in the Form of Lost Profits. Meridian's DermaTrūe acne-treatment product line experienced a significant revenue decline in the third quarter of 2025, temporally correlated with and causally attributable to the false campaign. The lost gross profits for Q3 2025 are estimated at $4.625 million, yielding an annualized lost-profit estimate of approximately $18.5 million if the campaign continues unabated.
2. Disgorgement of Apex's Incremental Profits. Apex's PuraClear product line experienced above-trend revenue growth during the same period, generating an estimated $19.8 million in incremental revenue attributable to the false campaign. At Apex's estimated gross margin of 56.5%, the disgorgeable incremental profits total approximately $11.2 million.
3. Enhanced (Treble) Damages Under the Lanham Act. If the Court finds that Apex acted willfully — and the fabricated clinical study citation and Apex's post-NAD defiance provide strong evidence of willfulness — the Lanham Act authorizes treble damages up to $55.5 million (i.e., $18.5 million × 3).
In addition to the foregoing, Meridian faces an imminent and independently quantifiable harm: Kingsley Drug Stores LLC, one of Meridian's largest retail partners, has notified Meridian that it will reduce DermaTrūe shelf space by 30% effective October 1, 2025, citing declining consumer demand. Meridian's sales team estimates the annual revenue impact of this reduction at $4.1 million, which translates to approximately $2.5625 million in additional annual lost gross profit. This figure is incremental to the Q3 2025 lost-profit analysis because the shelf-space reduction has not yet taken effect and is not reflected in the current quarter's revenue data.
Taking these categories together, the range of potential recovery is as follows:
• Conservative estimate (compensatory lost profits only, no enhancement): approximately $18.5–$21.1 million per year of continuing harm.
• Moderate estimate (lost profits plus disgorgement, no trebling): approximately $29.7–$32.3 million.
• Maximum estimate (treble damages plus full disgorgement plus attorneys' fees): potentially exceeding $66.7 million.
These figures are preliminary and are subject to material refinement upon receipt of Apex's actual financial data in discovery. To that end, Dr. Raymond Choe of Marlowe Asset Management Economic Consulting LLC has been retained at a billing rate of $925 per hour to prepare a formal damages report. Dr. Choe's engagement is discussed in greater detail in Section VIII below.
Meridian's action is to be filed in the United States District Court for the Southern District of New York. Our target filing date for the Complaint and the accompanying Motion for Preliminary Injunction is September 26, 2025.
II. BACKGROUND AND FACTUAL PREDICATE
A. The Parties
Meridian Consumer Brands LLC. Meridian is a Delaware limited liability company with its principal place of business at 410 West 34th Street, 18th Floor, New York, New York 10001. Meridian develops, markets, and distributes premium skincare and personal-care products through a diversified portfolio of brands sold in mass-market retail, specialty retail, and direct-to-consumer channels throughout the United States and in select international markets. Meridian's flagship product line is the DermaTrūe acne-treatment system, a clinically tested regimen that has been on the market since 2017 and has earned significant consumer recognition and brand loyalty in the acne-treatment category. Since 2019, Meridian has been a portfolio company of Brindoval Capital Partners Fund IV LP, a private equity fund that acquired a controlling interest in the company to support its growth strategy in the premium personal-care segment.
According to Meridian's audited financial statements for the fiscal year ended December 31, 2024, prepared by Ashford & Kline LLP, Meridian's total revenue for FY 2024 was $487.6 million. Of that total, the DermaTrūe product line contributed $138.2 million in revenue, representing approximately 28.3% of total company revenue. The DermaTrūe line has historically been Meridian's highest-margin and fastest-growing product family, and it is central to Meridian's strategic positioning in the competitive acne-treatment market.
Apex Naturals Inc. Apex is a Delaware corporation headquartered at 75 Commerce Boulevard, Suite 300, Parsippany, New Jersey 07054. Apex is a mass-market and "clean-beauty" skincare company that competes directly with Meridian in several product categories, including acne treatment. Apex's key competitive product in the acne-treatment space is its PuraClear line, which Apex has positioned as a value-priced, "clean-ingredient" alternative to premium acne-treatment systems such as DermaTrūe.
Based on publicly available market intelligence, trade publication reports, and industry analyst estimates — actual audited figures are not available and will be sought in discovery — Apex's total revenue for FY 2024 is estimated at approximately $312.4 million. The PuraClear product line is estimated to have generated approximately $89.7 million of that total, representing approximately 28.7% of Apex's total revenue. Like DermaTrūe for Meridian, PuraClear is understood to be a strategically critical product line for Apex and is the focus of significant marketing investment.
B. The False Advertising Campaign
On June 2, 2025, Apex launched a national comparative advertising campaign under the consumer-facing brand "The PuraClear Truth" (Apex internal code name: "Project Clarity"). The campaign was developed by Apex's advertising agency of record, Brightline Creative Partners LLC, under the supervision of Owen Prescott, Brightline's Chief Creative Officer. The campaign was disseminated across multiple channels, including national television, digital and social media platforms, in-store point-of-sale materials at major retail locations, print advertisements in consumer magazines, and a dedicated landing page on Apex's corporate website (www.apexnaturals.com/puraclear-truth).
Based on available market intelligence and media-monitoring data, the total estimated campaign spend for the period of June through August 2025 was approximately $23.0 million, broken down as follows: approximately $14.3 million allocated to television advertising (including national cable and broadcast network placements) and approximately $8.7 million allocated to digital and social media advertising (including paid search, display advertising, influencer partnerships, and sponsored content on platforms including Northpoint Services Inc., Dunmore & Co., and Crowne Albany Partners LLC). The magnitude of this spend — representing a substantial increase over Apex's historical marketing expenditure for the PuraClear line — reflects the deliberate and aggressive nature of the campaign.
The campaign makes three categories of false or materially misleading claims about Meridian's DermaTrūe products in comparison to Apex's PuraClear products:
(1) Fabricated Clinical Superiority Claim. The campaign's centerpiece is a claim that PuraClear is "clinically proven to clear acne 2× faster" than DermaTrūe, citing a purported publication: "Guerrero et al., 2024, Independent Dermatological Review." Our investigation has revealed that no such publication exists in any indexed medical or scientific journal. The actual basis for the claim appears to be a non-blinded, uncontrolled 22-person pilot study conducted internally by Apex's product development team under the direction of Dr. Simon Guerrero, Apex's Vice President of Product Development. A 22-person pilot study with no control group, no blinding, and no peer review does not constitute adequate substantiation for the comparative efficacy claims made in the campaign and, critically, the citation to a non-existent publication in a fabricated journal represents an affirmative misrepresentation to consumers and constitutes strong evidence of intentional falsity.
(2) Misleading Price Comparison. The campaign prominently features a price comparison asserting that PuraClear is "less than half the price" of DermaTrūe, presenting PuraClear's price of $12.99 for a 1.0 oz. tube alongside DermaTrūe's price of $28.99 for its Complete Acne System, which is a 5.2 oz. multi-product kit. This comparison is facially misleading because it compares unlike products in unlike quantities. On a per-ounce basis — the standard unit-price comparison used in the skincare industry and required by many retail pricing regulations — PuraClear costs $12.99 per ounce whereas DermaTrūe costs approximately $5.57 per ounce. In other words, when compared on an apples-to-apples basis, DermaTrūe is actually more than 50% less expensive per unit than PuraClear, the exact opposite of the impression the advertisement conveys.
(3) False "Clean" Ingredients Claim. The campaign asserts that PuraClear is the only acne-treatment line with "truly clean" ingredients, implying that DermaTrūe contains parabens, sulfates, and synthetic fragrances. This claim is false. Meridian reformulated the DermaTrūe Pure line in 2024, and the reformulated products are certified free of parabens, sulfates, and synthetic fragrances. This reformulation was verified by Beacon Scientific Laboratories LLC in Lab Report No. BSL-2025-0412, dated March 15, 2025. Apex's "clean" claim thus misrepresents the composition of a directly competing product and is likely to mislead consumers who are specifically seeking clean-ingredient alternatives.
The cumulative effect of these three categories of false claims is to create a materially distorted perception in the minds of consumers that PuraClear is clinically superior, substantially less expensive, and uniquely "clean" relative to DermaTrūe — none of which is true. As discussed in Section III below, consumer survey data confirms that this distorted perception has directly and measurably impacted consumer purchasing decisions and Meridian's market share.
C. Pre-Litigation History
The parties have had several exchanges and procedural interactions prior to the commencement of litigation:
• June 18, 2025: Derek Cho, Meridian's General Counsel, sent a detailed cease-and-desist letter to Tanya Fischetti, Apex's General Counsel, identifying each of the three categories of false claims, demanding that Apex immediately discontinue the "PuraClear Truth" campaign in its entirety, and reserving all of Meridian's rights and remedies under applicable law, including but not limited to the Lanham Act, New York General Business Law, and common law.
• July 3, 2025: Apex responded through outside counsel, Harrison Briggs of Caldwell, Briggs & Nolan LLP. The response categorically denied all allegations of false advertising, asserted that the claims in the campaign were adequately substantiated, and declined to modify or withdraw any aspect of the campaign. The letter did not provide any substantiation materials and adopted a confrontational posture that, in our view, further evidences Apex's willful disregard for the truth of its advertising claims.
• July 22, 2025: Meridian filed a formal complaint with the National Advertising Division ("NAD") of BBB National Programs, Inc. The complaint was assigned Case Reference No. NAD-2025-01847. The NAD complaint challenged all three categories of claims identified in the cease-and-desist letter.
• August 15, 2025: The NAD issued a preliminary recommendation that Apex discontinue or materially modify the challenged claims. Specifically, the NAD found that Apex had not provided adequate substantiation for the clinical superiority claim and that the price comparison was likely to mislead consumers. Notwithstanding this recommendation from the industry's self-regulatory body, Apex declined to comply and announced its intention to continue the campaign without modification. Apex's refusal to comply with the NAD recommendation is significant both as evidence of willfulness and as a factor that courts have considered in assessing the appropriateness of enhanced damages and injunctive relief.
• September 8, 2025: Following the failure of the NAD process to resolve the dispute, Meridian retained Calderwood & Harkness LLP to pursue federal litigation. This firm was engaged after a competitive selection process and was selected based on its experience in complex Lanham Act false advertising matters.
D. Key Financial Data Sources and Limitations
Before proceeding to the damages analysis, it is important to note the sources and limitations of the financial data underlying this preliminary assessment.
Meridian Financial Data. All financial data relating to Meridian's revenues, costs, and margins is sourced from MCB's internal profit-and-loss statements, audited financial statements prepared by Ashford & Kline LLP, and detailed sales reports provided by Julia Whitmore, Meridian's Chief Marketing Officer, and Derek Cho, General Counsel. These data are regarded as reliable and have been verified against the audit working papers to the extent available. However, certain allocations of fixed overhead and shared corporate costs will require further refinement by Dr. Choe for purposes of the formal damages model.
Apex Financial Data. Because Apex is a privately held corporation that does not publicly file audited financial statements, all financial data relating to Apex's revenues, costs, and margins are estimates derived from publicly available market intelligence, trade publications (including Beauty Industry Analyst Weekly, Cosmetics Business International, and IRI/Circana point-of-sale data), and industry benchmarking. These estimates are reasonable for purposes of this preliminary assessment, but will require validation and refinement through discovery. In particular, the estimated 56.5% gross margin applied to Apex's PuraClear line is based on industry benchmarks for comparable mass-market skincare companies and may differ materially from Apex's actual margins. Dr. Choe's formal report will be updated with Apex's actual financial data once produced in discovery.
Consumer Survey Data. The consumer perception data referenced in this memorandum was collected by Fisk Analytics Group LLC under the direction of Dr. Eleanor Fisk. The post-campaign survey was fielded on August 22, 2025, using a nationally representative sample of 1,500 adults aged 18 and older, with a margin of error of ±2.5% at the 95% confidence level. Baseline data was collected in a comparable survey conducted in January 2025 (prior to the campaign launch). These survey results provide important corroborating evidence of causation, linking the false campaign to measurable shifts in consumer perception of DermaTrūe.
III. COMPENSATORY DAMAGES — LOST PROFITS ANALYSIS
A. Legal Framework
The Lanham Act provides the primary statutory basis for Meridian's compensatory damages claim. Under Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), a plaintiff who prevails on a claim of false advertising under Section 43(a) of the Act, 15 U.S.C. § 1125(a), is entitled to recover "any damages sustained by the plaintiff" as a result of the defendant's wrongful conduct. Courts have consistently recognized that lost profits constitute the primary measure of compensatory damages in false advertising cases, as they represent the economic harm directly suffered by the plaintiff. See, e.g., Calderon Corporation Eprova AG v. Gnosis S.p.A., 760 F.3d 247 (2d Cir. 2014); PPX Enters., Inc. v. Audiofidelity Enters., Inc., 818 F.2d 266 (2d Cir. 1987).
In addition, Meridian's claims under New York General Business Law Sections 349 and 350 provide a supplementary basis for compensatory damages recovery. Under GBL § 349, a plaintiff may recover actual damages suffered as a result of deceptive business practices, and in some circumstances, treble damages up to $1,000 per individual consumer transaction. For a business plaintiff such as Meridian, the more significant relief under the GBL is the broad equitable relief available under these statutes, including injunctive relief and the recovery of actual business losses caused by the deceptive conduct.
The standard methodology for calculating lost profits in false advertising cases is the "but-for" analysis: the plaintiff must demonstrate the revenue it would have earned absent the defendant's wrongful conduct, less any costs that the plaintiff avoided as a result of not generating that revenue. In other words, the measure of damages is the incremental contribution margin (revenue less variable costs) that the plaintiff lost because consumers were diverted by the defendant's false advertising. The plaintiff bears the burden of proving its lost profits with reasonable certainty, but is not required to establish them with mathematical precision. The Second Circuit has held that "the amount of damages need not be proven with precision" and that "doubts about the precise amount of damages are resolved against the wrongdoer." George Basch Co. v. Blue Coral, Inc., 968 F.2d 1532, 1540 (2d Cir. 1992).
B. DermaTrūe Revenue Decline — Q3 2025
The starting point for Meridian's lost-profits analysis is the measurable decline in DermaTrūe revenue during Q3 2025, the first full quarter following the launch of the "PuraClear Truth" campaign on June 2, 2025. The relevant revenue figures are as follows:
• DermaTrūe Q3 2024 Revenue (Baseline): $36.8 million
• DermaTrūe Q3 2025 Revenue (Post-Campaign): $29.4 million
• Revenue Decline: $36.8M − $29.4M = $7.4 million
• Percentage Decline: $7.4M ÷ $36.8M = 20.1%
The temporal correlation between the campaign launch and the revenue decline is strong and direct. DermaTrūe's revenue trajectory was stable to growing through Q1 2025 and the first month of Q2 2025, consistent with its historical growth pattern. The decline commenced in the weeks immediately following the June 2, 2025 launch of the "PuraClear Truth" campaign and accelerated through the balance of Q3 2025, with the steepest declines observed in August 2025 — the period during which the campaign's television placements reached peak frequency.
Importantly, there are no other material market events that would explain the magnitude or timing of this decline. Meridian did not experience any product recalls, safety issues, or negative regulatory actions during this period. Meridian did not reformulate or repackage the DermaTrūe line in a manner that would have disrupted sales. No significant new competitor entered the acne-treatment market during Q2–Q3 2025 that would have diverted consumer demand. And there were no material changes in Meridian's distribution, pricing, or promotional activity that would account for the observed decline. In short, the "PuraClear Truth" campaign is the most plausible — and, we believe, the only reasonable — explanation for the timing and magnitude of the DermaTrūe revenue shortfall.
The consumer-perception survey data collected by Dr. Eleanor Fisk of Fisk Analytics Group LLC strongly corroborates this causation analysis. The post-campaign survey, fielded on August 22, 2025, revealed the following shifts in consumer perception of DermaTrūe relative to the January 2025 baseline:
• "Overpriced" perception: 34% of respondents who recalled the PuraClear advertisements believed DermaTrūe was "overpriced," compared to only 11% in the January 2025 baseline — a 23-percentage-point increase.
• "Less effective" perception: 27% of respondents who recalled the PuraClear advertisements believed DermaTrūe was "less effective than PuraClear," compared to only 8% in the January 2025 baseline — a 19-percentage-point increase.
These perception shifts map directly onto the two principal categories of false claims in the campaign: the misleading price comparison (driving the "overpriced" perception) and the fabricated clinical superiority claim (driving the "less effective" perception). The survey data thus provides a compelling evidentiary bridge between the false campaign and the lost revenue, reinforcing the causal inference drawn from the temporal correlation analysis.
C. Gross Margin and Lost Gross Profit Calculation
Having established the revenue decline attributable to the false campaign, the next step is to convert that revenue decline into a lost gross profit figure by applying Meridian's gross margin percentage.
According to Meridian's internal profit-and-loss statements, verified against the audit working papers of Ashford & Kline LLP, the DermaTrūe product line operates at a gross margin of 62.5%. This means that for every dollar of DermaTrūe revenue, Meridian retains $0.625 after accounting for cost of goods sold (raw materials, manufacturing, packaging, and direct labor), which represents 37.5% of revenue.
Applying this margin to the Q3 2025 revenue decline:
• Q3 2025 Lost Gross Profit: $7.4 million × 62.5% = $4.625 million
This figure represents the incremental contribution margin that Meridian would have earned but for Apex's false campaign. The variable costs avoided — i.e., the cost of goods sold that Meridian would have incurred had it generated the additional $7.4 million in revenue — are properly excluded from the damages calculation because they would have been consumed in the production of the goods.
A question arises as to whether any incremental fixed costs should also be considered in the lost-profits analysis. Fixed costs — such as manufacturing facility overhead, fixed-component salaries, lease payments, and depreciation — do not vary with the volume of production and therefore are typically not deducted from lost-profits calculations. In Meridian's case, this treatment is particularly appropriate because MCB had excess manufacturing capacity during Q3 2025. The manufacturing facilities were not operating at full capacity, and the additional $7.4 million in revenue could have been produced without any incremental fixed-cost expenditure. Dr. Choe will verify this conclusion as part of his formal analysis, but we are confident in the preliminary determination that the 62.5% gross margin is the appropriate measure of Meridian's incremental lost profits.
D. Annualized Lost-Profit Estimate
If the "PuraClear Truth" campaign continues unabated — and all indications are that Apex intends to continue the campaign indefinitely, having rejected both the cease-and-desist letter and the NAD recommendation — the lost-profit figure of $4.625 million per quarter can be annualized as follows:
• Annualized Lost Gross Profit: $4.625 million × 4 quarters = $18.5 million per year
This estimate is conservative for several reasons:
(i) It assumes no further market-share erosion beyond the Q3 2025 run rate. In reality, false advertising campaigns that continue over time tend to produce compounding effects as the misleading narrative becomes more deeply embedded in consumer perceptions. The damage from each additional quarter of the campaign is likely to exceed, not merely equal, the damage from Q3 2025.
(ii) It does not include the cascading effects of lost shelf space. As discussed in Section VI below, Kingsley Drug Stores LLC has already announced a 30% reduction in DermaTrūe shelf space effective October 1, 2025. If other major retailers follow suit — as is common when a leading chain signals diminished demand for a product — the revenue impact will exceed the Q3 2025 run rate by a significant margin. The annualized estimate does not capture these cascading distribution losses.
(iii) It does not account for diminished brand equity. The DermaTrūe brand has been built over eight years of investment in clinical testing, marketing, and consumer education. The false campaign is eroding this accumulated brand equity in ways that may not be fully captured by short-term revenue data. The long-term cost of brand rehabilitation — including corrective advertising, increased promotional spending, and diminished pricing power — could substantially exceed the direct revenue losses measured here.
(iv) It does not adjust for seasonal variation. Historically, DermaTrūe has experienced stronger sales in Q1 and Q2, corresponding with back-to-school purchasing in the spring and seasonal skincare transitions. Q3 is not DermaTrūe's peak selling season. Consequently, the Q3 2025 revenue decline, while significant, may understate the annual impact if the campaign's effects persist into higher-volume quarters.
If injunctive relief is obtained — and our motion for a preliminary injunction will be filed on September 26, 2025 — the period of direct lost profits attributable to the campaign may be limited. However, it is well established in false advertising jurisprudence that the harmful effects of a false advertising campaign do not cease immediately upon the campaign's withdrawal. Consumer perceptions formed by false advertising tend to persist, and the process of correcting those perceptions requires time and investment. Dr. Choe will model a "tail" period of residual harm extending beyond any injunction, taking into account the rate at which consumer perceptions revert to baseline following the cessation of a false advertising campaign. Based on comparable cases and academic literature on advertising decay rates, a residual harm period of 12 to 24 months is a reasonable preliminary assumption.
E. Sensitivity Analysis
Because the precise magnitude of the revenue decline attributable to the false campaign is subject to some uncertainty, we have prepared a preliminary sensitivity analysis that brackets the likely range of lost-profit outcomes under varying assumptions:
The low case assumes that the actual revenue decline somewhat overstates the campaign's impact — perhaps because a small portion of the decline is attributable to general market softness or other minor factors. We consider this scenario unlikely given the strength of the temporal correlation and the consumer survey data, but it provides a useful floor for the damages range.
The base case reflects the actual Q3 2025 data and is the most reliable estimate for the current period.
The high case assumes that the campaign's effects continue to intensify, particularly as the Kingsley shelf-space reduction takes effect and as the campaign's cumulative exposure deepens consumer misperceptions. We consider this scenario plausible if the campaign continues through Q4 2025 and into 2026 without injunctive intervention.
Dr. Choe will develop a more granular sensitivity analysis incorporating additional variables, including different assumptions regarding the tail period of residual harm, seasonal adjustment factors, and alternative causal-attribution methodologies.
IV. DISGORGEMENT OF DEFENDANT'S PROFITS
A. Legal Framework
In addition to compensatory damages in the form of the plaintiff's lost profits, Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), authorizes recovery of "defendant's profits" as a separate measure of relief. The availability of disgorgement serves both a compensatory function — ensuring that the plaintiff is made whole for injuries that may be difficult to quantify as lost profits — and a deterrent function — preventing the defendant from retaining the fruits of its wrongful conduct.
In the Second Circuit, disgorgement of a defendant's profits in a false advertising case under the Lanham Act requires a showing that the defendant's conduct was willful or that equity otherwise requires such an award. See Romag Fasteners, Inc. v. Fossil, Inc., 590 U.S. 169 (2020) (holding that willfulness is a "highly important" consideration but not an absolute prerequisite for a profits award under § 1117(a)). As discussed in Section V below, the evidence of willfulness in this case is strong.
Under the established burden-shifting framework, the plaintiff's initial burden is to prove the defendant's gross revenue attributable to the wrongful conduct. Once the plaintiff establishes gross revenue, the burden shifts to the defendant to demonstrate any costs or deductions that should be applied to reduce the gross revenue figure to a net profit amount. See 15 U.S.C. § 1117(a) ("In assessing profits the plaintiff shall be required to prove defendant's sales only; defendant must prove all elements of cost or deduction claimed."). This burden-shifting mechanism is designed to prevent the defendant from benefiting from its own failure to maintain or produce adequate financial records.
B. Apex's Incremental PuraClear Revenue
The starting point for the disgorgement analysis is an estimate of the incremental revenue that Apex's PuraClear product line generated as a result of the false campaign — that is, revenue above and beyond what PuraClear would have generated on its historical trajectory absent the campaign.
Based on available market intelligence, PuraClear's FY 2024 revenue was approximately $89.7 million, implying average quarterly revenue of approximately $22.4 million. To estimate the incremental revenue attributable to the false campaign, Dr. Choe has conducted a preliminary analysis comparing PuraClear's actual Q2–Q3 2025 sales against a trend-line projection based on PuraClear's Q2–Q3 2024 performance, adjusted for the overall growth rate of the acne-treatment market during the relevant period.
This analysis yields an estimated incremental PuraClear revenue for Q2–Q3 2025 of approximately $19.8 million. This figure represents the above-trend revenue — i.e., the revenue that PuraClear generated in excess of what it would have been expected to generate on its historical growth trajectory absent the false advertising campaign. The $19.8 million figure captures two quarters of above-trend performance (the campaign launched on June 2, 2025, affecting the balance of Q2 and all of Q3 2025).
It is important to note that this estimate is preliminary and is based on market intelligence and publicly available data rather than Apex's actual internal sales records. The precise quantification of Apex's incremental revenue will require production of Apex's detailed sales data in discovery, including unit and revenue data broken down by product SKU, distribution channel, and geographic market. We will seek this data through our initial document requests and a Rule 30(b)(6) deposition notice directed at Apex's designated corporate witness with knowledge of PuraClear financial performance.
C. Disgorgement Calculation
Having estimated Apex's incremental PuraClear revenue at $19.8 million, we next apply Apex's estimated gross margin to arrive at a disgorgeable profit figure.
Based on Dr. Choe's preliminary analysis of industry benchmarks for mass-market skincare companies with product profiles comparable to Apex's PuraClear line, as well as limited public disclosures by Apex, the estimated gross margin for PuraClear products is 56.5%. Applying this margin:
• Disgorgeable Incremental Profits: $19.8 million × 56.5% = $11.187 million, rounded to $11.2 million
Several important considerations bear on this figure:
First, under the Lanham Act's burden-shifting framework, once Meridian establishes Apex's gross revenue of $19.8 million (or whatever figure is ultimately supported by the evidence), the burden shifts to Apex to demonstrate its deductible costs. If Apex is unable to adequately substantiate its claimed costs — for example, because of poor record-keeping or because certain cost categories are not properly allocable to the PuraClear line specifically — the disgorgement figure could be higher than $11.2 million, potentially approaching the full gross revenue figure.
Second, the $23.0 million total campaign spend by Apex (comprising $14.3 million in television advertising and $8.7 million in digital and social media advertising) is not automatically deductible from the disgorgement calculation. Courts have consistently held that advertising expenditures that are themselves instruments of the wrongful conduct — i.e., the very expenditures through which the false claims were disseminated — should not be credited as deductions in the defendant's favor. See, e.g., Synergistic Int'l, LLC v. Korman, 470 F.3d 162, 175 (4th Cir. 2006) (noting that costs of deception should not reduce the amount of disgorgement). To permit Apex to deduct the cost of its false advertising from the profits generated by that same advertising would be to reward the wrongdoer and undermine the deterrent purpose of the disgorgement remedy.
Third, as with the lost-profits estimate, the 56.5% gross margin applied to Apex's incremental revenue is an estimate based on industry benchmarks and will need to be validated against Apex's actual financial records in discovery. Apex's actual gross margin may be higher or lower than 56.5%, which would correspondingly increase or decrease the disgorgement figure.
D. Overlap Analysis — Lost Profits vs. Disgorgement
An important analytical question is the extent to which the lost-profits damages and the disgorgement damages overlap — that is, whether the two measures compensate Meridian for the same injury, which could raise concerns about duplicative recovery.
Not all of Apex's incremental gains necessarily came at Meridian's expense. Some of the $19.8 million in above-trend PuraClear revenue may have been diverted from other competitors in the acne-treatment market rather than from DermaTrūe specifically. Some portion may also represent market expansion — consumers who were induced by the campaign to purchase an acne-treatment product but who would not otherwise have purchased any acne-treatment product at all, from either Meridian or Apex.
Our preliminary position is that the two measures of damages compensate for different injuries and that a court may appropriately award both, subject to the overriding principle against double recovery. Lost profits compensate Meridian for the sales it lost as a direct result of the false campaign. Disgorgement compensates Meridian for the unjust enrichment of Apex and serves a deterrent function that is independent of the plaintiff's actual losses. The Second Circuit has recognized this distinction and has held that courts have broad discretion to award both lost profits and disgorgement where different harms are being addressed and there is no duplicative recovery. See Calderon Corporation Eprova AG v. Gnosis S.p.A., 760 F.3d 247, 264 (2d Cir. 2014).
Dr. Choe will develop a formal overlap model that quantifies the portion of Apex's incremental revenue that is attributable to diversion from DermaTrūe specifically versus diversion from other competitors or market expansion. To the extent that overlapping portions are identified, the aggregate damages figure will be adjusted accordingly to avoid double recovery. For purposes of this preliminary assessment, we present the lost-profits and disgorgement figures as separate categories, recognizing that the actual combined award may be adjusted downward to account for overlap.
V. ENHANCED (TREBLE) DAMAGES UNDER THE LANHAM ACT
A. Legal Framework
Section 35(a) of the Lanham Act, 15 U.S.C. § 1117(a), grants the court discretion to "enter judgment, according to the circumstances of the case, for any sum above the amount found as actual damages, not exceeding three times such amount." This enhancement provision permits the court to treble the plaintiff's actual damages award in cases where the defendant's conduct is found to be willful or where the case is deemed "exceptional."
The willfulness standard requires evidence that the defendant acted with actual knowledge of the falsity of its advertising claims or with reckless disregard for the truth or falsity of those claims. The Second Circuit has articulated this standard as requiring "proof that the defendant had knowledge that [its] imitation would cause consumer confusion" or, in the false advertising context, knowledge that the advertising was false or misleading. See George Basch Co. v. Blue Coral, Inc., 968 F.2d 1532, 1540 (2d Cir. 1992); Int'l Star Class Yacht Racing Ass'n v. Tommy Hilfiger U.S.A., Inc., 146 F.3d 66 (2d Cir. 1998).
In addition to treble damages, the Lanham Act provides that the court may award reasonable attorneys' fees to the prevailing party in "exceptional cases." 15 U.S.C. § 1117(a). The Supreme Court has held that an exceptional case is "simply one that stands out from others with respect to the substantive strength of a party's litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated." Octane Fitness, LLC v. ICON Health & Fitness, Inc., 572 U.S. 545, 554 (2014) (construing the parallel provision in the Patent Act, which has been applied by analogy to the Lanham Act).
B. Treble Damages Calculation
Applying the treble-damages multiplier to the annualized lost-profit figure:
• Treble Damages (Maximum): $18.5 million × 3 = $55.5 million
It is important to note that the treble-damages multiplier is discretionary and represents the statutory maximum. Courts may award a lesser enhancement — for example, double damages — if they determine that full trebling is not warranted under the circumstances. Conversely, the treble-damages multiplier applies to the "amount found as actual damages," which may be higher or lower than the annualized figure used here depending on the damages period ultimately established at trial and the final determination of the actual damages amount.
The evidence in this case strongly supports a finding of willfulness and, accordingly, the imposition of enhanced damages at or near the statutory maximum. The following factors are particularly compelling:
(i) Fabricated Clinical Study Citation. The centerpiece of the campaign is a clinical superiority claim attributed to "Guerrero et al., 2024, Independent Dermatological Review" — a publication that does not exist. The fabrication of a scientific citation in a consumer-facing advertisement is qualitatively different from, and more egregious than, the garden-variety exaggeration that might characterize ordinary competitive advertising. It is an intentional misrepresentation that could only have been created with knowledge of its falsity. This evidence alone, if corroborated through discovery of internal communications, should be sufficient to establish willfulness.
(ii) Post-NAD Defiance. The NAD, the advertising industry's self-regulatory body, issued a preliminary recommendation on August 15, 2025 that Apex discontinue or materially modify the challenged claims. Apex declined to comply. While an NAD recommendation is not legally binding, Apex's refusal to honor the industry's self-regulatory process is probative of its willful intent to continue disseminating claims it knows or should know to be false. Courts have considered NAD findings as evidence in Lanham Act cases, and Apex's refusal to comply undermines any argument that it acted in good faith.
(iii) Magnitude of Campaign Spend. The $23.0 million campaign spend demonstrates that "The PuraClear Truth" was not an isolated or inadvertent misstatement. It was a deliberate, carefully planned, and massively funded initiative to reshape consumer perceptions through false comparative claims. The scale of the investment evidences a calculated strategic decision rather than an innocent mistake.
(iv) Litigation Posture of Defiance. Apex's July 3, 2025 response to Meridian's cease-and-desist letter, transmitted through Harrison Briggs of Caldwell, Briggs & Nolan LLP, was confrontational and dismissive, offering no substantiation for the challenged claims and refusing even to engage in a dialogue about the accuracy of the advertising. This posture is relevant to the Court's assessment of willfulness and exceptionalness.
We anticipate that discovery will yield additional evidence of willfulness, including internal communications among Apex's senior leadership — Marcus Devlin (CEO), Rachel Emory (CMO), Dr. Simon Guerrero (VP, Product Development), and Tanya Fischetti (General Counsel) — that may reveal the deliberative process behind the decision to cite a non-existent study and to continue the campaign despite the NAD recommendation.
C. Attorneys' Fees
As noted above, Section 35(a) of the Lanham Act permits an award of reasonable attorneys' fees in "exceptional cases." If the evidence supports a finding of willfulness sufficient to warrant treble damages, it will a fortiori support a finding that this is an exceptional case warranting an award of attorneys' fees.
Calderwood & Harkness LLP's 2025 billing rates are as follows:
All time expended on this matter is being tracked contemporaneously through the firm's standard time-entry system and will be documented in detail for purposes of a fee petition at the appropriate stage of the litigation. We anticipate that total fees through trial could be substantial given the complexity of the case and the anticipated volume of discovery.
VI. ADDITIONAL DAMAGES — KINGSLEY DRUG STORES SHELF-SPACE REDUCTION
A. Factual Basis
On August 5, 2025, Kingsley Drug Stores LLC ("Kingsley"), one of Meridian's largest and most strategically important retail partners, notified Meridian's sales team that it was reducing the DermaTrūe product line's shelf space allocation by 30%, effective October 1, 2025. Kingsley is a major national retail chain operating over 2,400 stores across 38 states and is a key distribution channel for the DermaTrūe line. The notification cited "declining consumer demand" as the basis for the reduction.
The timing and stated rationale for Kingsley's decision align directly with the false advertising campaign. The "declining consumer demand" cited by Kingsley is the same demand erosion documented in the Q3 2025 revenue data and the consumer perception shifts identified in the Fisk Analytics survey. In other words, the false campaign caused consumers to perceive DermaTrūe as overpriced and less effective than PuraClear, which in turn drove down sales through the Kingsley channel, which in turn prompted Kingsley to reduce DermaTrūe's shelf space — a cascading chain of causation that is both direct and foreseeable.
Meridian's sales team, led by Julia Whitmore (CMO), estimates that the annual revenue impact of the 30% shelf-space reduction at Kingsley will be approximately $4.1 million.
B. Damages Theory
The Kingsley shelf-space reduction gives rise to damages claims under two distinct theories.
First, it provides the basis for additional compensatory damages representing the lost sales that Meridian will suffer through the Kingsley channel as a direct result of the reduced product visibility and availability. Shelf space is a critical determinant of retail sales volume in the personal-care category. Products with less prominent or less extensive shelf-space allocations consistently generate lower sales, regardless of their intrinsic quality or brand recognition. The 30% reduction in DermaTrūe shelf space will directly and predictably reduce Meridian's sales through one of its most important retail channels.
Second, the shelf-space reduction supports the tortious interference with business relations claim that Meridian intends to assert as the fifth cause of action in its Complaint. By disseminating false and misleading advertising that artificially depressed demand for DermaTrūe, Apex interfered with Meridian's business relationship with Kingsley — a relationship that had been stable and mutually beneficial for years — and caused Kingsley to take an adverse action (the shelf-space reduction) that it would not have taken absent the false campaign.
Critically, the $4.1 million annual revenue figure is incremental to the Q3 2025 lost-profit analysis presented in Section III. The shelf-space reduction takes effect on October 1, 2025 — the first day of Q4 2025 — and thus is not yet reflected in the Q3 2025 revenue data on which the base-case lost-profit analysis is built. The Kingsley impact represents a new and additional source of harm that will compound the existing revenue erosion beginning in Q4 2025.
Moreover, the long-term implications of the shelf-space reduction extend well beyond the immediate revenue impact. In the retail personal-care industry, shelf-space reductions at a major chain like Kingsley can have significant cascading effects. Other retailers — including national drugstore chains, mass merchandisers, and grocery retailers — monitor competitor shelving decisions and frequently adjust their own product assortments in response. If other major retailers follow Kingsley's lead in reducing DermaTrūe shelf space, the revenue impact could multiply significantly. Furthermore, regaining lost shelf space once it has been ceded is notoriously difficult and typically requires substantial promotional spending, reduced trade pricing, and extended negotiation periods with retail buyers. The competitive dynamics of retail shelf-space allocation mean that space lost by DermaTrūe is likely to be filled by competing products — potentially including PuraClear — making it even more difficult to recover the lost distribution.
C. Calculation
The preliminary damages calculation for the Kingsley shelf-space reduction is as follows:
• Annual Lost Revenue from Kingsley Channel: $4.1 million
• Gross Margin: 62.5% (consistent with overall DermaTrūe margin)
• Annual Lost Gross Profit from Kingsley Channel: $4.1 million × 62.5% = $2.5625 million
Adding this figure to the annualized lost-profit estimate from Section III yields a combined annual lost-profit figure of approximately $21.1 million ($18.5 million base case + $2.5625 million Kingsley impact).
However, this layered approach requires further refinement by Dr. Choe to avoid potential double-counting. Specifically, if the base-case annualized estimate (which extrapolates Q3 2025 quarterly data to a full-year figure) already implicitly assumes that the Q3 revenue decline rate will persist into subsequent quarters, and if the Kingsley shelf-space reduction begins to affect Q4 sales, there is a theoretical risk that some portion of the Kingsley impact may be captured in a forward-looking annualization of the base-case decline rate. Dr. Choe's formal model will disaggregate these two sources of harm and ensure that the combined figure accurately captures the total incremental damage without overlap.
VII. SUMMARY OF PRELIMINARY DAMAGES ESTIMATES
A. Tabular Summary
The following table summarizes the preliminary damages estimates across all categories analyzed in this memorandum:
B. Range of Total Recovery
Based on the foregoing analysis, the range of potential total recovery is as follows:
Conservative (lost profits only, no enhancement): Approximately $18.5–$21.1 million per year of continuing harm, representing the compensatory lost-profit claim without any disgorgement or enhanced damages. This is the minimum recovery floor, assuming that Meridian prevails on liability and establishes causation.
Moderate (lost profits + disgorgement, no trebling): Approximately $29.7–$32.3 million, representing the compensatory lost-profit claim combined with full disgorgement of Apex's incremental profits, but without the treble-damages enhancement. This range reflects the view that the evidence will support both measures of recovery, subject to the overlap adjustment discussed in Section IV.D.
Maximum (treble damages + disgorgement + fees): Potentially exceeding $66.7 million, calculated as $55.5 million in treble damages (based on annualized lost profits of $18.5 million × 3) plus $11.2 million in disgorgement of Apex's incremental profits, plus reasonable attorneys' fees in an amount to be determined. This figure represents the theoretical ceiling and is achievable only if the Court finds willfulness, exercises its discretion to impose the full treble-damages multiplier, and awards both disgorgement and enhanced damages without a downward adjustment for overlap.
It is important to note that courts will not permit duplicative recovery. The actual award will depend on the specific evidence developed in discovery, the Court's exercise of its broad equitable discretion under the Lanham Act, and the extent to which the trier of fact finds that the different damages categories address different injuries. The figures presented above are preliminary and are intended to frame the range of potential outcomes for purposes of litigation strategy and the preliminary injunction motion.
VIII. DATA GAPS AND DISCOVERY PRIORITIES
The damages estimates set forth in this memorandum are based on the best available data as of the date of this memorandum. However, as noted throughout, several critical data points are estimated or unavailable and will require targeted discovery to validate and refine. This section identifies the key data gaps and outlines the corresponding discovery priorities.
A. Information Needed from Apex
The following categories of information will be sought from Apex through document requests, interrogatories, and Rule 30(b)(6) depositions:
1. PuraClear Sales Data. Actual unit and revenue data for all PuraClear products for the period from Q1 2024 through Q3 2025, broken down by SKU, distribution channel (e.g., retail, e-commerce, direct-to-consumer), and geographic market. This data is essential to validate the preliminary estimate of $19.8 million in incremental PuraClear revenue and to refine the disgorgement calculation in Dr. Choe's formal model.
2. Cost of Goods Sold and Margin Data. Actual cost of goods sold and gross margin figures for PuraClear products, including raw material costs, manufacturing costs, packaging costs, and direct labor allocations. This data is needed to replace the estimated 56.5% gross margin with verified figures and to provide Apex the opportunity to meet its burden of proving deductible costs under the Lanham Act's burden-shifting framework for disgorgement.
3. Campaign Spend Documentation. Detailed invoices, media-buy records, and insertion orders from Brightline Creative Partners LLC (Owen Prescott, Chief Creative Officer), Apex's advertising agency of record, to verify the estimated $23.0 million total campaign spend and to analyze the deductibility vel non of those expenditures. We will also seek Apex's internal budget documents and approval records for the "Project Clarity" / "PuraClear Truth" campaign.
4. Clinical Study Underlying the Superiority Claim. All protocols, raw data, subject-consent forms, statistical analyses, draft and final reports, and internal and external communications relating to the 22-person pilot study and the purported "Guerrero et al., 2024, Independent Dermatological Review" publication. This material is critical to establishing the fabrication of the clinical citation and to supporting the willfulness findings that underpin the treble-damages claim. We will specifically seek all communications among Dr. Simon Guerrero, Rachel Emory, and Tanya Fischetti regarding the decision to cite a non-existent publication.
5. Internal Communications. Emails, text messages, instant messages (including Meridian Solutions, Teams, or other internal messaging platforms), memoranda, meeting notes, and other documents among Marcus Devlin (CEO), Rachel Emory (CMO), Dr. Simon Guerrero (VP, Product Development), Tanya Fischetti (General Counsel), and any other Apex personnel involved in the conception, development, approval, or continuation of the "PuraClear Truth" campaign. We are particularly interested in communications concerning: (a) the substantiation (or lack thereof) for the campaign's claims; (b) the decision to cite the fabricated "Guerrero et al." publication; (c) the response to Meridian's cease-and-desist letter; (d) the NAD proceeding and the decision to defy the NAD recommendation; and (e) any internal assessments of the campaign's impact on PuraClear sales and market share.
6. Retailer Sales Data. Apex's sales data through Kingsley Drug Stores LLC and comparable major retail channels, to assess whether PuraClear gained corresponding shelf space or sales volume as DermaTrūe lost shelf space and sales. This data will support the causation and tortious interference theories and will help Dr. Choe model the overlap between the lost-profits and disgorgement calculations.
B. Information Needed from Third Parties
1. Kingsley Drug Stores LLC. We will serve third-party subpoenas on Kingsley seeking documentation of the shelf-space decision, including internal analyses of DermaTrūe sales performance, category management reports, and any communications between Kingsley and Apex (or Apex's representatives) regarding PuraClear product placement, promotional support, or shelf-space allocation. This documentation will be critical to establishing (a) that the shelf-space reduction was a direct consequence of the false campaign rather than an independent business decision by Kingsley, and (b) whether Apex actively solicited the reallocation of DermaTrūe shelf space to PuraClear products, which would strengthen the tortious interference claim.
2. Additional Retailer Data. We will also seek sales-through and market-share data from other major retail and e-commerce channels through which both DermaTrūe and PuraClear are sold. This data will corroborate the causal link between the campaign and DermaTrūe's overall revenue decline and will help establish that the impact was not limited to a single retail channel but was felt across Meridian's entire distribution network.
C. Expert Work Streams
Three expert witnesses have been or will be engaged to support the damages case. Their respective work streams are summarized below:
1. Dr. Raymond Choe, Marlowe Asset Management Economic Consulting LLC ($925/hr). Dr. Choe will prepare the formal damages report, including: (a) a rigorous lost-profits model incorporating but-for revenue analysis, margin verification, and incremental-cost assessment; (b) a disgorgement analysis based on Apex's actual financial data (once obtained in discovery); (c) an overlap assessment to determine the extent to which the lost-profits and disgorgement measures address duplicative versus independent injuries; and (d) a model of the residual "tail" harm that will persist after any injunction, including estimated advertising decay rates and brand-rehabilitation costs. We anticipate Dr. Choe's engagement will require approximately 80 to 120 hours for the preliminary expert report, with additional hours for rebuttal work, deposition preparation, and trial testimony.
2. Dr. Eleanor Fisk, Fisk Analytics Group LLC ($850/hr). Dr. Fisk has already conducted the post-campaign consumer perception survey referenced throughout this memorandum. She may be called upon to conduct supplemental survey work if needed to establish additional consumer-confusion and materiality metrics for purposes of the damages causation analysis. In particular, if Apex challenges the causal link between the campaign and DermaTrūe's revenue decline, Dr. Fisk may conduct a conjoint or choice-based survey to estimate the diversion rate attributable to each of the three categories of false claims.
3. Dr. Miriam Salazar, Graystone University Medical Center ($750/hr). Dr. Salazar, a board-certified dermatologist and clinical researcher, will provide a scientific rebuttal of the clinical superiority claim. Her testimony will address the methodological deficiencies of the 22-person pilot study (lack of blinding, absence of a control group, inadequate sample size), the non-existence of the cited "Guerrero et al., 2024" publication, and the scientific consensus regarding acne-treatment efficacy comparisons. Her testimony is directly relevant to the willfulness determination because it will establish that no reasonable scientist or corporate officer could have believed that the 22-person pilot study supported the comparative claims made in the campaign. Dr. Salazar's work thus supports the foundation for the treble-damages claim.
IX. PRELIMINARY INJUNCTION DAMAGES CONSIDERATIONS
The damages analysis set forth in this memorandum serves an important dual purpose: in addition to quantifying the potential monetary recovery, the analysis supports the showing of irreparable harm that is essential to Meridian's forthcoming motion for a preliminary injunction, which we intend to file on September 26, 2025.
For purposes of the preliminary injunction standard, the damages analysis demonstrates that monetary damages alone are inadequate to make Meridian whole for several reasons:
(i) Ongoing Brand Erosion Is Difficult to Quantify with Precision. While this memorandum provides reasonable estimates of the monetary impact of the false campaign, the full extent of the brand damage is inherently uncertain and will unfold over time in ways that cannot be captured by a single point-in-time damages figure. Brand equity is an intangible asset that is built over years and can be eroded rapidly by false comparative advertising. The difficulty of quantifying brand damage with precision is itself a form of irreparable harm that weighs in favor of injunctive relief.
(ii) The Kingsley Shelf-Space Reduction Is Imminent and May Be Irreversible. The 30% shelf-space reduction at Kingsley Drug Stores is scheduled to take effect on October 1, 2025 — just fifteen days after our target filing date. Once shelf space is lost, it is extremely difficult to recover, as the competitive dynamics of retail category management typically allocate recaptured space to competing products. The imminence of this harm underscores the urgency of injunctive relief. If the Court enters a preliminary injunction requiring Apex to cease the false campaign, Meridian can use the injunction as the basis for discussions with Kingsley to forestall or reverse the shelf-space reduction.
(iii) Consumer-Perception Shifts Are Not Easily Remedied by Monetary Damages After the Fact. The Fisk Analytics survey documented dramatic shifts in consumer perception: 34% of campaign-aware respondents now believe DermaTrūe is "overpriced" (up from 11% at baseline) and 27% believe DermaTrūe is "less effective" than PuraClear (up from 8% at baseline). These perception shifts represent reputational harm that, once embedded in consumer consciousness, cannot simply be "undone" by a monetary award months or years later at the conclusion of litigation. Injunctive relief now will